  There is evidence that the population of cells that experience fluctuating
oxygen levels are more radioresistant than chronically hypoxic ones and hence,
this population may determine radiotherapy (RT) response, in particular for
hypofractionated RT, where reoxygenation may not be as prominent. A
considerable effort has been devoted to examining the impact of hypoxia on
hypofractionated RT; however, much less attention has been paid to cyclic
hypoxia specifically and the role its kinetics may play in determining the
efficacy of these treatments. Here, a simple mathematical model of cyclic
hypoxia and fractionation effects was worked out to quantify this. Cancer
clonogen survival fraction was estimated using the linear quadratic model,
modified to account for oxygen enhancement effects and inter-fraction tissue
oxygen kinetics. The resulting survival fraction formula was used to derive an
expression for the iso-survival biologically effective dose, $\bedeff$. These
were computed for some common extra-cranial hypofractionated radiotherapy
regimens. Using relevant literature parameter values, inter-fraction
fluctuations in oxygenation were found to result in an added 1-2 logs of
clonogen survival fraction in going from five fractions to one for the same
nominal biologically effective dose. $\bedeff$'s for most
ultra-hypofractionated (five or fewer fractions) regimens in a given tumour
site are similar in magnitude, suggesting iso-efficacy for common fractionation
schedules. Although significant, the loss of cell-killing with increasing
hypofractionation is not nearly as large as previous estimates based on the
assumption of complete reoxygenation between fractions. Most
ultra-hypofractionated regimens currently in place offer sufficiently high
doses to counter this loss of cell killing, although care should be taken in
implementing single-fraction regimens.
